Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.41 |
| ▸ | NPC1 | O15118 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5554755 | 0.86 | NPC1 (0.55) | RAB9AKDM4ENPC1KMT2APOLB | |
| SCHEMBL5556402 | 0.86 | KMT2A (0.46) | RAB9AKDM4ENPC1KMT2APOLB | |
| SCHEMBL5554739 | 0.85 | RAB9A (0.48) | RAB9AKDM4ENPC1KMT2APOLB | |
| SCHEMBL5554752 | 0.84 | KDM4E (0.40) | RAB9AKDM4ENPC1KMT2APOLB | |
| SCHEMBL5551156 | 0.84 | RAB9A (0.42) | RAB9AKDM4ENPC1KMT2APOLB | |
| SCHEMBL5556418 | 0.83 | KDM4E (0.56) | RAB9AKDM4ENPC1KMT2APOLB | |
| SCHEMBL5550907 | 0.83 | KMT2A (0.56) | RAB9AKDM4ENPC1KMT2APOLB | |
| SCHEMBL5556386 | 0.81 | KMT2A (0.46) | RAB9AKDM4ENPC1KMT2APOLB | |
| SCHEMBL5550841 | 0.81 | POLB (0.42) | RAB9AKDM4ENPC1KMT2APOLB | |
| SCHEMBL1564437 | 0.81 | CHEK1 (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010556-A1 | Thiophene derivatives as chk 1 inhibitors | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| EP-1732920-A2 | THIOPHENE DERIVATIVES AS CHK 1 INHIBITORS | AstraZeneca AB (SE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005066163-A2 | THIOPHENE DERIVATIVES AS CHK 1 INIHIBITORS | ASTRAZENECA AB (SE) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010556-A1 | Thiophene derivatives as chk 1 inhibitors | CHEK1, CHKA, CHEK2 | RAB9A 2722/4885KDM4E 713/4885NPC1 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.